Big pharma can only see the benefit of R&D for wealthy markets | Kenan Malik
Link Share :https://www.theguardian.com/commentisfree/2019/may/05/big-pharma-can-only-see-the-benefit-of-r-and-d-for-rich-markets
- via RSS
There is too little incentive for pharmaceutical companies to work on treatments for diseases of low-income countries
At the end of April, health workers in Malawi, Ghana and Kenya began rolling out the first and so far only vaccine proved to protect against malaria. It’s part of a World Health Organization pilot programme that could immunise more than one million children by 2023. Yet, while this is a welcome step in the fight against malaria, it also exposes the problems in developing vaccines for use in non-western countries.
This kind of endeavour can’t be repeated, from GSK’s point of view
作者暂无likerid, 赞赏暂由本网站代持，当作者有likerid后会全部转账给作者（我们会尽力而为）。Tips: Until now, everytime you want to store your article, we will help you store it in Filecoin network. In the future, you can store it in Filecoin network using your own filecoin.
Support author:
Author's Filecoin address:
Or you can use Likecoin to support author: